Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (-) metastatic breast cancer.

被引：0
|
作者：
Tryfonopoulos, Dimitrios
Tzouda, Vasiliki
Zouki, Dionysia
Kyriakidou, Athina
Sarris, Evangelos
Grivas, Anastasios
Gouveris, Panagiotis
Papaxoinis, George
Demiri, Stamatina G.
机构：
[1] St Savas AntiCanc Hosp, Athens, Greece
[2] Hosp Agios Savvas, Athens, Greece
[3] Agios Savvas Canc Hosp, Athens, Greece
[4] Agios Savvas Anticanc Hosp, Athens, Greece
[5] Agios Savvas Anticanc Hosp, Athens, CT, Greece
[6] Agios Savvas Anticanc Hosp, Dept Med Oncol 2, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13034
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Watanabe, J.
    Hamauchi, S.
    Higashi, Y.
    Onozawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients
    Due, Asbjorn
    Berg, Tobias
    Jensen, Maj-Britt
    Yammeni, Sophie
    Volmer, Lone
    Brems-Eskildsen, Anne Sofie
    Andersen, Klaus Kaae
    Rana, Saeeda
    Knoop, Ann
    Kuemler, Iben
    ACTA ONCOLOGICA, 2023, 62 (02) : 126 - 133
  • [33] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR +/HER2-Breast Cancer at a Single Cancer Center
    Kovacevic, M. Milovic
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    BREAST, 2023, 68 : S46 - S46
  • [34] Everolimus in heavily pretreated metastatic breast cancer: Is real world experience different?
    Bajpai, J.
    Ramaswamy, A.
    Gupta, S.
    Ghosh, J.
    Gulia, S.
    INDIAN JOURNAL OF CANCER, 2016, 53 (03) : 464 - 467
  • [35] Safety and efficacy of lapatinib (L)-based therapy in heavily pretreated HER2+metastatic breast cancer (MBC) patients (pts): A single institution experience
    Sepulveda, J. M.
    De Velasco, G.
    Manso, L.
    Ghanem, I.
    Ciruelos Gil, E. M.
    Vega, E.
    Mendiola, C.
    Cortes-Funes, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] CLINICAL EXPERIENCE WITH METRONOMIC CHEMOTHERAPY IN HEAVILY PRETREATED METASTATIC BREAST CANCER PATIENTS
    Gavila, J.
    Guerrero, A.
    Ruiz, A.
    Climent, M. A.
    Poveda, A.
    Guillem, V.
    Ruiz, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 74 - 74
  • [37] Trabectedin in heavily pretreated and elderly metastatic soft tissue sarcomas - a single center experience
    Hoiczyk, M.
    Grabellus, F.
    Taeger, G.
    Schuler, M.
    Bauer, S.
    ONKOLOGIE, 2011, 34 : 237 - 237
  • [38] FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2-Metastatic Breast Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (04): : SP315 - SP315
  • [39] HER-2/neu oncogene amplification in breast cancer.
    Depowski, PL
    Brien, TP
    Sheehan, CE
    Muraca, PJ
    Stylos, S
    Johnson, RL
    Ross, JS
    LABORATORY INVESTIGATION, 1998, 78 (01) : 18A - 18A
  • [40] Fulvestrant in heavily pretreated patients with advanced breast cancer:: experience from a Named Patient Programme in Switzerland
    Hawle, H.
    Thuerlimann, B.
    Pagani, O.
    Buser, K.
    Bonnefoi, H.
    Forni, M.
    Aapro, M.
    Mach, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
12345